Browse by Audience
Skip to content
Papers of the Week
Dihydroergotamine mesylate nasal spray: an acute treatment option for migraine in adults.
Authors
Silvestro M, Orologio I, Tessitore A, Trojsi F, Tedeschi G, Russo AAbstract
Although the landscape of migraine symptomatic treatment has been enriched by novel effective drugs, it is mandatory to critically reappraise older molecules to ascertain whether they could still represent reliable alternatives in specific endophenotypes of patients or migraine attacks. Among these, dihydroergotamine (DHE) nasal spray has been shown to be effective and is characterized by greater tolerability and manageability than the parenteral DHE formulation.